Discovery of Potent Anti-Mpro Inhibitors for Covid-19 Treatment using Alpha-ketoamide Derivatives
Potent nanomolar inhibitors of SARS-CoV-2 main protease with strong cell-based antiviral activity.
Researchers at Purdue University have discovered that an alpha-ketoamide derivative potently inhibited Covid-19 in cell culture assay. This inhibitor has shown unprecedented antiviral potency against SARS-COV-2 in VERO cells. This compound exerted potent activity in VERO-E6 cells.
Technology Validation:
In cellulo assays in VERO cells.
Advantages:
-IC50 in low nanomolar range
-In cellulo activity
Applications:
-SARS-CoV-2
TRL: Pharmaceuticals
Intellectual Property:
Provisional-Gov. Funding, 2020-04-23, United States
Provisional-Gov. Funding, 2020-12-01, United States
PCT-Gov. Funding, 2021-02-23, WO
NATL-Patent, 2021-02-23, Mexico
NATL-Patent, 2021-02-23, Canada
NATL-Patent, 2021-02-23, Brazil
NATL-Patent, 2021-02-23, India
NATL-Patent, 2021-02-23, Russia
NATL-Patent, 2021-02-23, Europe
NATL-Patent, 2021-02-23, China
NATL-Patent, 2021-02-23, Australia
NATL-Patent, 2021-02-23, Japan
NATL-Patent, 2021-02-23, Republic of Korea
NATL-Patent, 2022-10-21, United States
DIV-Patent, 2025-06-20, Japan
Keywords: COVID, Medical/Health, Pharmaceuticals, SARS-CoV-2